This article mainly discusses the relationship between the active treatment concept of the systemic lupus erythematosus (SLE) and its positive outcome in long-term prognosis,which is the overall prognosis of SLE benefits from the improvement on the liying conditions of patients with lupus nephritis (LN).Although more argumentations are still required in regards to whether to use the different general conclusions of the meta analysis between the childhood-onset SLE (cSLE) and the early adulthood-onset SLE patients at the same age as more proactive induction therapy in early phase,yet the time point for early therapy before clinical symptoms appearing can be determined and thereby positive anticipation can be achieved through keeping the difference between the long-term prognosis of the cSLE and the adult-onset patients as evidences,and making in-depth study on the innate laws of the heterogeneity of cSLE,meanwhile giving biological markers more application which can be highly reliable in reflecting the morbid status,supported by the study outcomes of pharmacogenetics/pharmacogenomics and further optimization of current immunoregulation/immune inhibitors approaches (as evidences required by long-term effects).